Bioretec
1.86
EUR
+2.2 %
BRETEC
First North Finland
Medical Equipment & Services
Health Care
1,434 following
+2.2%
-12.68%
-34.97%
-29.81%
-22.5%
-18.42%
-36.95%
-
-36.75%
bioretec.com/investors/investors-in-english
Bioretec is a medical technology company. The company specializes in the development of medical devices. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other material for bone and soft tissue injuries. In addition to the main business, service and associated ancillary services are also offered. Bioretec operates worldwide with the largest presence in the Nordic region.
P/E (adj.) (24e)
-8.23
EV/EBIT (adj.) (24e)
-8.16
P/B (24e)
9.53
Dividend yield-% (24e)
-
Target price
2.40 EUR
Recommendation
Accumulate
Updated
15.11.2024
First North Finland
BRETEC
Daily low / high price
1.83 / 1.93
EUR
Market cap
37.83M EUR
Turnover
175.63K EUR
Volume
93K
Business risk
Valuation risk
Current
Previous
Analyst
Antti Siltanen
Analyst
Income statement
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5 | 2.0 | 2.9 | 3.9 | 4.2 | 7.0 | 10.6 | 16.1 |
| growth-% | -14.2 % | 33.6 % | 46.9 % | 32.8 % | 6.6 % | 68.5 % | 51.4 % | 51.1 % |
| EBITDA | -2.1 | -2.8 | -2.0 | -2.8 | -4.3 | -3.4 | -0.7 | 1.5 |
| EBIT (adj.) | -1.9 | -2.7 | -2.3 | -3.0 | -4.4 | -3.7 | -1.6 | 0.6 |
| EBIT | -1.9 | -2.7 | -2.3 | -3.0 | -4.4 | -3.7 | -1.6 | 0.6 |
| Profit before taxes | -2.3 | -6.0 | -2.4 | -3.8 | -4.4 | -3.9 | -2.1 | 0.2 |
| Net income | -2.3 | -6.0 | -2.4 | -3.8 | -4.4 | -3.9 | -2.1 | 0.2 |
| EPS (adj.) | -0.02 | -0.43 | -0.17 | -0.20 | -0.23 | -0.20 | -0.11 | 0.01 |
| growth-% | ||||||||
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio |
Profitability and return on capital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -137.8 % | -141.6 % | -68.0 % | -72.6 % | -102.3 % | -48.6 % | -6.1 % | 9.4 % |
| EBIT-% (adj.) | -128.4 % | -133.1 % | -77.9 % | -77.7 % | -105.9 % | -52.2 % | -15.5 % | 3.7 % |
| EBIT-% | -128.4 % | -133.1 % | -77.9 % | -77.7 % | -105.9 % | -52.2 % | -15.5 % | 3.7 % |
| ROE | -4,642.9 % | -211.2 % | -77.8 % | -74.7 % | -73.4 % | -205.8 % | 190.3 % | -10.0 % |
| ROI | -90.4 % | -54.8 % | -46.8 % | -42.9 % | -52.5 % | -61.8 % | -29.6 % | 10.4 % |
Valuation
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 2.70 | 1.40 | 2.18 | 1.86 | 1.86 | 1.86 | 1.86 | |
| Shares | 150.4 | 14.1 | 14.1 | 19.1 | 19.5 | 19.5 | 19.5 | 19.5 |
| Market cap | 38.1 | 19.8 | 41.7 | 36.3 | 36.3 | 36.3 | 36.3 | |
| Enterprise value | 33.5 | 20.1 | 37.2 | 36.0 | 41.2 | 43.5 | 43.7 | |
| EV/S | - | 16.7 | 6.8 | 9.5 | 8.6 | 5.9 | 4.1 | 2.7 |
| EV/EBITDA | - | - | - | - | - | - | - | 28.8 |
| EV/EBIT (adj.) | - | - | - | - | - | - | - | 72.7 |
| EV/EBIT | - | - | - | - | - | - | - | 72.7 |
| P/E (adj.) | - | - | - | - | - | - | - | 174.9 |
| P/E | - | - | - | - | - | - | - | 174.9 |
| P/B | - | 8.8 | 10.3 | 5.1 | 9.5 | - | - | - |
| P/S | - | 19.0 | 6.7 | 10.7 | 8.7 | 5.2 | 3.4 | 2.3 |
| Dividend yield | ||||||||
| Equity ratio | 35.0 % | 50.3 % | 55.0 % | 77.2 % | 62.2 % | -0.9 % | -40.0 % | -31.9 % |
| Gearing ratio | -16.2 % | -107.1 % | 17.9 % | -54.5 % | -9.1 % | -9,005.9 % | -330.3 % | -372.9 % |
Quarter data
| Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24 | Q4/24e | 2024e | Q1/25e | Q2/25e | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.0 | 3.9 | 0.7 | 1.4 | 0.7 | 1.4 | 4.2 | 1.4 | 1.7 |
| EBITDA | -1.8 | -2.8 | -1.1 | -0.8 | -1.4 | -1.0 | -4.3 | -1.0 | -0.9 |
| EBIT | -1.8 | -3.0 | -1.1 | -0.8 | -1.4 | -1.1 | -4.4 | -1.0 | -0.9 |
| Profit before taxes | -1.7 | -3.8 | -1.1 | -0.8 | -1.4 | -1.1 | -4.4 | -1.1 | -1.0 |
| Net income | -1.7 | -3.8 | -1.1 | -0.8 | -1.4 | -1.1 | -4.4 | -1.1 | -1.0 |
ShowingAll content types
The commercialization of Bioretec's RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement
Bioretec Ltd's business review January-September 2024: Launch of the RemeOs™ Trauma Screw in the U.S. is proceeding to the next phase, EU authorization in the final stage
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools